Tradestie Institutional Equity Comparison Engine

CELUW vs HUMAW โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-08-25 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CELUW Overall Edge

CELUW Captures Institutional Edge (1โ€“0 Pillars ยท 1โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CELUW (CELUW) driven by superior Momentum & Technical. Fundamentally, CELUW trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus HUMAW at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CELUW sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against HUMAW sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CELUW N/M vs HUMAW N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner CELUW
1Y -95.2% vs -99.8% ยท 52W Pos 2% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CELUW US Equity
CELUW
Institutional Equity
$0.00
+533.33% 1D
Market Cap N/A
1M Return -54.76%
1Y Return -95.25%
Forward P/E N/M
Unified AI Score
41.3 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 50.0
HUMAW NASDAQ
Humacyte, Inc. Warrant
Biological Products, (No Disgnostic Substances)
$0.00
-78.05% 1D
Market Cap N/A
1M Return -91.0%
1Y Return -99.82%
Forward P/E N/M
Unified AI Score
47.3 / 100 HOLD
Tech 33.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CELUW -95.25% HUMAW -99.82% Spread: +2.38 pp (CELUW Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CELUW TTM Op. Margin: N/A HUMAW TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELUW vs HUMAW. Trailing 12-month operating profitability (CELUW N/A vs HUMAW N/A) and valuation multiples (CELUW N/M vs HUMAW N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CELUW (1) vs HUMAW (2)
Institutional Metric CELUW HUMAW Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 2% ($0โ€“$0) 0% ($0โ€“$1) Stronger Trend CELUW
Beta / 30D Volatility Risk Regime 1.52ฮฒ ยท 2163% Vol 0.62ฮฒ ยท 437% Vol Lower Realized Risk HUMAW
Unified Institutional Score Composite Signal 41.3 / 100 (SELL) 47.3 / 100 (HOLD) Higher Composite HUMAW

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CELUW vs HUMAW Buy Guide
CELUW UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CELUW Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
HUMAW UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live HUMAW Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CELUW nor HUMAW registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.